What You Should Know:
– CorVista Health, a Toronto-based digital health company dedicated to improving cardiovascular disease diagnosis, announced it has closed a $65 million Series C financing, bringing the total funding to nearly $100 million.
– This significant capital provides a runway for ongoing research, development and commercialization efforts for CorVista® System, the company’s non-invasive, point-of-care solution that allows physicians to rapidly test for heart disease.
– The CorVista System is intended to synchronously collect and apply machine learning to a patient’s cardiac and hemodynamic signals to predict the likelihood of cardiovascular diseases without the use of radiation, contrast agents, injections, fasting or exercise.
– Within minutes of the test, the CorVista Analysis is available in a secure web portal to aid physicians in rapidly diagnosing and treating patients with suspected cardiovascular disease, answering important clinical questions to guide better treatment decisions.
